Objective: To investigate the application value of trastuzumab combined with FOLFOX6 chronomodulated chemotherapy for patients with HER2 positive advanced metastatic gastric cancer. Methods: The clinical data of 70 patients with HER2 positive advanced metastatic gastric cancer were analyzed retrospectively. According to different administration methods, the patients were divided into control group and observation group, with 35 cases in each group. The control group was treated with trastuzumab combined with FOLFOX6 conventional chemotherapy, while the observation group was treated with trastuzumab combined with FOLFOX6 chronomodulated chemotherapy. The curative effect, adverse reactions, cellular immune function indexes and quality of life of the two groups were compared. Results: There was no significant difference between the general data and therapeutic effects of the two groups (P＞0.05). The incidence of shivering or fever, rash, gastrointestinal reaction, peripheral neurotoxicity and bone marrow suppression in the observation group were significantly lower than those in the control group (P＜0.05). The levels of CD3+, CD4+ and CD4+/CD8+ of the observation group were significantly higher than those of the control group (P＜0.05). The KPS score of the observation group was significantly higher than that of the control group (P＜0.05). Conclusion: Treatment of HER2 positive advanced metastatic gastric cancer with trastuzumab combined with FOLFOX6 chronomodulated chemotherapy can reduce the incidence of adverse reactions, improve cellular immune function and reduce the impact of chemotherapy on the quality of life of patients.
SONG Yuanrui
,
GUAN Zhe
,
MO Yanli
,
ZHENG Wentao
. Therapeutic effect of chronomodulated chemotherapy and routine chemotherapy in patients with HER2 positive gastric cancer[J]. Journal of Baotou Medical College, 2023
, 39(6)
: 62
-66
.
DOI: 10.16833/j.cnki.jbmc.2023.06.013
[1] 中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)胃癌诊疗指南-2021[M]. 北京:人民卫生出版社, 2021: 73-73.
[2] 曾海, 谢茜, 王茜, 等. 替吉奥为基础的化疗方案一线治疗晚期胃癌的Meta分析[J].现代肿瘤医学, 2021, 29(6): 994-998.
[3] 黄军, 蒙光化, 罗再琴, 等. TPF方案时辰诱导化疗联合同步放化疗治疗局部晚期鼻咽癌的近期疗效观察[J]. 基层医学论坛, 2019, 23(1): 15-18.
[4] 狄潘潘, 贾淑云. 抗肿瘤药物的时辰药理学研究进展[J].肿瘤药学, 2020, 10(2):159-165.
[5] Ballesta A, Innominato PF, Dallmann R, et al. Systems chronotherapeutics[J].Pharmacol Rev, 2017, 69(2): 161-199.
[6] 曹冉华, 苏乌云, 呼群, 等. 曲妥珠单抗联合SOX方案治疗HER-2阳性晚期胃癌的临床疗效观察[J]. 现代生物医学进展, 2017, 17(4): 680-683.
[7] 皋文君, 刘砚燕, 袁长蓉. 国际肿瘤化疗药物不良反应评价系统: 通用不良反应术语标准4.0版[J]. 肿瘤, 2012, 32(2): 142-144.
[8] 王燕艳, 郭联斌, 谭世余. 曲妥珠单抗联合FOLFOX方案治疗HER-2阳性晚期胃癌的疗效及安全性研究[J]. 现代医学, 2019, 47(2): 170-174.
[9] 庄晓虹, 孟杰, 林舒, 等. 曲妥珠单抗联合化疗对HER2阳性胃癌患者血清肿瘤标记物及远期疗效的影响[J]. 现代消化及介入诊疗, 2019, 24(7): 702-706.
[10] 梁良, 孙丽, 沈小钢, 等. 奥沙利铂联合卡培他滨辅助化疗与ECF方案治疗老年进展期胃癌的效果及毒副反应对比[J]. 中国老年学杂志, 2017, 37(19): 4826-4828.
[11] 彭小东, 宋来. 中国胃癌患者时辰化疗疗效及安全性的Meta分析[J]. 四川生理科学杂志, 2018, 40(3): 171-176.
[12] Balboa JBP, Pereira roche N, Castellanos MSR, et al. DNA damage, repair of single strand breaks, total antioxidant capacity and reduced glutathione levels in female patients with a family history of cancer[J]. Free Radic Biol Med, 2017, 108: S44.
[13] 万山, 金风, 吴伟莉, 等. 两种不同给药速度的时辰化疗联合调强放疗治疗局部晚期鼻咽癌的临床研究[J]. 中华放射医学与防护杂志, 2018, 38(4): 278-284.
[14] 冯梓贤, 曾今诚, 吴培信, 等. 术前放疗同期FOLFOX6时辰化疗在局部进展期直肠癌中的应用[J]. 西部医学, 2017, 29(7): 949-957.
[15] 舒宏博, 金风, 吴伟莉, 等. 同期放化疗联合诱导或辅助时辰化疗治疗局部晚期鼻咽癌的临床观察[J]. 临床肿瘤学杂志, 2021, 26(7): 615-621.
[16] 周宁, 王晖, 黄莹莹, 等. PD-1单抗联合赫塞汀治疗HER2阳性晚期胃癌长期生存一例[J]. 中华老年医学杂志, 2021,40(4): 506-508.
[17] 甄生华, 梁赅, 丁薛祥. 曲妥珠单抗联合替吉奥单药治疗老年HER-2阳性晚期胃癌的近远期疗效及对血清肿瘤标志物表达的影响[J]. 现代消化及介入诊疗, 2020, 25(6): 764-767.
